GlassScriptPhysician profile
Robert P Castellucci
NPI 1952336026
$7,225.83
in general payments reported to CMS, 2019-2025
46 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,393 · 2020: $1,228 · 2021: $623 · 2022: $811 · 2023: $614 · 2024: $706 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.54 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,837.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $587.82 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $449.10 | 2019-2022 | |
| Amgen INC. | $404.13 | 2019-2025 | Tepezza, Repatha, Evenity |
| Insulet Corporation | $384.03 | 2019-2025 | Omnipod |
| Amarin Pharma, INC. | $336.31 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $321.07 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $320.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.41 | 2019-2025 | Jardiance |
| Dexcom, INC. | $308.32 | 2019-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $183.36 | 2019-2024 | Unithroid |
| Valeritas, INC. | $160.06 | 2019 | |
| Cequr Corporation | $132.78 | 2023-2025 | Cequr Simplicity |
| Corcept Therapeutics | $122.55 | 2019-2023 | Korlym |
| Antares Pharma, INC. | $114.44 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $100.78 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $98.15 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Shire North American Group INC | $94.73 | 2019 | |
| Lifescan, INC. | $73.91 | 2020-2023 | |
| Kowa Pharmaceuticals America, INC. | $71.50 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $66.57 | 2019-2020 | |
| Abbvie INC. | $57.48 | 2019-2022 | |
| Mannkind Corporation | $57.04 | 2020-2024 | |
| Medtronic Minimed, INC. | $53.24 | 2019-2020 | |
| Ibsa Pharma INC. | $52.60 | 2019-2021 | |
| Beta Bionics, INC. | $47.08 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $46.36 | 2020 | |
| Horizon Therapeutics Plc | $40.84 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $40.54 | 2023-2025 | Yorvipath |
| Pfizer INC. | $37.05 | 2019-2021 | |
| Aytu Biopharma, INC. | $33.76 | 2019 | |
| Abbott Laboratories | $33.16 | 2021-2022 | |
| Esperion Therapeutics, INC. | $30.50 | 2025 | Nexletol |
| Intuity Medical INC | $27.74 | 2022 | |
| Becton, Dickinson and Company | $24.22 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.76 | 2022 | |
| Medtronic, INC. | $18.13 | 2025 | Minimed 780g |
| Chiesi USA, INC. | $17.81 | 2025 | Mycapssa |
| Rhythm Pharmaceuticals, INC. | $16.52 | 2025 | Imcivree |
| Amryt Pharma Holdings LTD | $16.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.33 | 2020 | |
| Sequel Med Tech, LLC | $15.28 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $14.48 | 2022 | |
| Embecta Corp. | $12.93 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Janssen Pharmaceuticals, INC | $11.67 | 2019 | |
| Clarus Therapeutics INC. | $9.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Castellucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.